In the United States, the Food and Drug Administration (FDA) approved rufinamide in 2008 to be used as an add-on (adjunctive) seizure medicine in children 4 years and older and adults with the Lennox-Gastaut (LGS) syndrome.
Rufinamide (ru-FIN-uh-mide) is the generic name (non-brand name) of a seizure medicine.
It is used to treat:
Lennox-Gastaut Syndrome